Nav: Home

Know thy enemy: Kill MRSA with tailored chemistry

December 22, 2016

UConn medicinal chemists have developed experimental antibiotics that kill MRSA, a common and often deadly bacteria that causes skin, lung, and heart infections. The success is due to their strategy, which found a weakness and exploited it in a way the bacteria should have trouble countering, the researchers report in the Dec. 22 issue of Cell Chemical Biology.

Cases of MRSA (Methicillin-Resistant Staphylococcus aureus) are on the rise and increasingly resistant to common antibiotics. The first choice treatment for MRSA, trimethoprim-sulfamethoxazole, is relatively safe and inexpensive. But trimethoprim-resistant MRSA has begun to spread around the globe. Up to 30% of infections in sub-Saharan African no longer respond to it, and significant numbers in Europe and Asia as well. UConn medicinal chemists Amy Anderson, Dennis Wright and Ph.D. student Stephanie Reeve have been working to develop a drug that will be harder for MRSA to evolve resistance against. They had several candidates in the works when they asked colleagues at UConn Health and Hartford Hospital to start collecting trimethoprim-resistant strains of MRSA as test cases.

"Although resistance [to trimethoprim] in the community is generally less than 10% in our local area, resistance elsewhere is climbing. Additionally, many vulnerable patient populations cannot take trimethoprim-sulfamethoxazole or other generic drugs because of side effects they may cause, and new agents are needed," says Dr. Michael Nailor, a UConn pharmacologist co-funded with Hartford Hospital.

The local samples showed just how fast antibiotic resistance is spreading. Six of nine bacterial strains collected had genes for trimethoprim resistance that had never before been seen in the US. The strains were also variously resistant to other antibiotics such as erythromycin and tetracycline.

But they didn't stand a chance against the experimental antibiotics from Anderson, Wright and Reeve's lab.

"We've actually taken strains [of MRSA] from the clinic and shown our compounds work. We were really happy about these results," says Stephanie Reeve. Their strategy had worked.

"One of the most exciting aspect of this work was that we had worked hard to design broadly acting inhibitors against many different resistant forms of the enzymes and these designs proved very effective against two new enzymes we had never considered or previously studied," says Wright. The strategic approach the chemists had taken was to target the bacteria's use of Vitamin B9. Also known as folate, it's as critical to MRSA bacteria as it is to us. Block its action and a vital enzyme pathway is shut down. The bacteria die. Trimethoprim is currently the only antibacterial antifolate available, and bacteria have evolved different versions of the folate enzyme that aren't impaired by it. But Anderson, Wright and Reeve thought they should be able to make other, better antifolates. They painstakingly analyzed the molecular structure of the enzyme they were up against, and exactly how it needed to interact with other molecules to do its job. Only by understanding its form and function could they foil versions of the enzyme they'd never seen before, Wright says.

Armed with their knowledge, they designed new antifolates. These drugs are crafted to bind the enzyme in such a way that if the enzyme changes enough to evade them, it won't be able to do its job with vitamin B9, either. That will hopefully make it harder for bacteria to evolve resistance. The drugs' success against the trimethoprim-resistant strains of MRSA sampled so far bodes well.

The team is now gathering more MRSA from across the country. Dr. Jeffrey Aeschlimann, a UConn Health associate professor of pharmacy practice says, "We'd like to determine if the resistance mechanisms we discovered in our local MRSA strains are also found in other clinics throughout the United States. We also may find other novel resistance mechanisms. In both cases, we will be able to gain even more valuable information about our how our new antibiotics work against MRSA."
-end-


University of Connecticut

Related Bacteria Articles:

Conducting shell for bacteria
Under anaerobic conditions, certain bacteria can produce electricity. This behavior can be exploited in microbial fuel cells, with a special focus on wastewater treatment schemes.
Controlling bacteria's necessary evil
Until now, scientists have only had a murky understanding of how these relationships arise.
Bacteria take a deadly risk to survive
Bacteria need mutations -- changes in their DNA code -- to survive under difficult circumstances.
How bacteria hunt other bacteria
A bacterial species that hunts other bacteria has attracted interest as a potential antibiotic, but exactly how this predator tracks down its prey has not been clear.
Chlamydia: How bacteria take over control
To survive in human cells, chlamydiae have a lot of tricks in store.
Stress may protect -- at least in bacteria
Antibiotics harm bacteria and stress them. Trimethoprim, an antibiotic, inhibits the growth of the bacterium Escherichia coli and induces a stress response.
'Pulling' bacteria out of blood
Magnets instead of antibiotics could provide a possible new treatment method for blood infection.
New findings detail how beneficial bacteria in the nose suppress pathogenic bacteria
Staphylococcus aureus is a common colonizer of the human body.
Understanding your bacteria
New insight into bacterial cell division could lead to advancements in the fight against harmful bacteria.
Bacteria are individualists
Cells respond differently to lack of nutrients.

Related Bacteria Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Changing The World
What does it take to change the world for the better? This hour, TED speakers explore ideas on activism—what motivates it, why it matters, and how each of us can make a difference. Guests include civil rights activist Ruby Sales, labor leader and civil rights activist Dolores Huerta, author Jeremy Heimans, "craftivist" Sarah Corbett, and designer and futurist Angela Oguntala.
Now Playing: Science for the People

#521 The Curious Life of Krill
Krill may be one of the most abundant forms of life on our planet... but it turns out we don't know that much about them. For a create that underpins a massive ocean ecosystem and lives in our oceans in massive numbers, they're surprisingly difficult to study. We sit down and shine some light on these underappreciated crustaceans with Stephen Nicol, Adjunct Professor at the University of Tasmania, Scientific Advisor to the Association of Responsible Krill Harvesting Companies, and author of the book "The Curious Life of Krill: A Conservation Story from the Bottom of the World".